恒瑞医药：瑞维鲁胺片药物临床试验获批

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Ruvelimab tablets for prostate cancer, marking a significant step in its ongoing research and development efforts [1] Group 1 - The company announced on November 3 that it has been granted permission to conduct Phase III clinical trials for Ruvelimab tablets [1] - Ruvelimab tablets were previously approved for market in 2022, specifically for the treatment of high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [1]